Evotec and BMS intensify R&D on protein degradersHamburg-headquartered Evotec SE has extended and expanded its three-year-old partnership with Bristol Myers Squibb in targeted protein degradation ("molecular glue degraders") for an additional … more ➔
Replacing beef with cellular protein halves deforestationReplacing 20% of global beef consumption with fermentation-derived microbial protein by 2050 could halve annual deforestation and associated carbon dioxide emissions. more ➔
Hot of the press: BIOTECH Insight NewsletterDeutsche Börse report key growth figures of the German biotech sector in 2021 in BIOTECH Insight, its new online information service published in collaboration with BIOCOM AG. more ➔
Engimmune Therapeutics raises CHF15.5m in seed financingCancer specialist Engimmune Therapeutics has raised CHF15.5m in a seed financing to expand its pipeline of T-cell receptor therapeutics. more ➔
Switzerland shows sustained growth of biotech sectorThe Swiss Biotech sector has again attracted record-breaking investments in 2021, according to the Swiss Biotech Report that was presented at the Swiss Biotech Day 2022 in Basel. more ➔
Commission to establish EU health data spaceDigital medicine holds great opportunities. The EU Commission is therefore presenting a draft law this week that defines rules for a European Health Data Space. more ➔
Four new autoantigens trigger multiple sclerosisSwiss and Swedish researchers have uncovered four previously unkown autoantigens that trigger multiple sclerosis in mice. more ➔
TWB partners with Processium and SyngulonIndustrial biotech project managment specialist Toulouse White Biotech (TWB) has joined forces with process developer Processium and industrial synbio start-up Syngulon. more ➔
Meat consumption must fall by at least 75 percentIf our planet is to continue feeding us in the future, rich countries must significantly reduce their meat consumption by at least 75% suggests a new study by German researchers. more ➔
Vigeneron updates gene therapy collab with Daiichi SankyoViGeneron and Daiichi Sankyo have agreed a follow-on collaboration to evaluate vgAAVs as vectors for Daiichi Sankyo’ novel treatment of prevalent eye diseases. more ➔
